Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 10/2006

01-10-2006

Improving Resectability of Hepatic Colorectal Metastases: Expert Consensus Statement

Authors: Eddie K. Abdalla, MD, René Adam, MD, PhD, Anton J. Bilchik, MD, PhD, Daniel Jaeck, MD, Jean-Nicolas Vauthey, MD, David Mahvi, MD

Published in: Annals of Surgical Oncology | Issue 10/2006

Login to get access

Excerpt

Colorectal cancer is the third most common malignancy in Western countries.1,2 Approximately 50% of patients with colorectal cancer develop hepatic metastases during the course of the disease.3‐5 The liver is the most common site of metastases of colorectal cancer, and hepatic metastases are responsible for death in at least two thirds of patients with colorectal malignancy.3,4 …
Literature
1.
Rastogi T, Hildesheim A, Sinha R. Opportunities for cancer epidemiology in developing countries. Nat Rev Cancer 2004;4:909–17CrossRefPubMed
2.
Bouvier AM, Remontet L, Jougla E et al. Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol 2004;28:877–81CrossRefPubMed
3.
4.
Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 1979;189:496–502CrossRefPubMed
5.
Faivre J, Manfredi S, Bouvier AM. [Epidemiology of colorectal cancer liver metastases]. Bull Acad Natl Med 2003;187:815–22PubMed
6.
Yamamoto J, Shimada K, Kosuge T et al. Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br J Surg 1999;86:332–7CrossRefPubMed
7.
Minagawa N, Nakayama Y, Hirata K et al. Correlation of plasma level and immunohistochemical expression of vascular endothelial growth factor in patients with advanced colorectal cancer. Anticancer Res 2002;22:2957–63PubMed
8.
Ercolani G, Grazi GL, Ravaioli M et al. Liver resection for multiple colorectal metastases: influence of parenchymal involvement and total tumor volume, vs number or location, on long-term survival. Arch Surg 2002;137:1187–92CrossRefPubMed
9.
Choti MA, Sitzmann JV, Tiburi MF et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759–66CrossRefPubMed
10.
Abdalla EK, Vauthey JN, Ellis LM et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818–25CrossRefPubMed
11.
Mann CD, Metcalfe MS, Leopardi LN, Maddern GJ. The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch Surg 2004;139:1168–72CrossRefPubMed
12.
Adam R, Lucidi V, Bismuth H. Hepatic colorectal metastases: methods of improving resectability. Surg Clin North Am 2004;84:659–71CrossRefPubMed
13.
Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644–57CrossRefPubMed
14.
Adam R, Pascal G, Castaing D et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240:1052–61CrossRefPubMed
15.
16.
17.
Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994;343:1405–10CrossRefPubMed
18.
Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663–9CrossRefPubMed
19.
Ong SY. Neoadjuvant chemotherapy in the management of colorectal metastases: A review of the literature. Ann Acad Med Singapore 2003;32:205–11PubMed
20.
Rougier P, Guimbaud R, Mitry E, Vaillant JN. [Chemotherapy with curative intent before (neoadjuvant) or after (adjuvant) surgery for colorectal cancer liver metastases]. Bull Acad Natl Med 2003;187:881–92PubMed
21.
Masi G, Allegrini G, Cupini S et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol 2004;15:1766–72CrossRefPubMed
22.
Pozzo C, Basso M, Cassano A et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004;15:933–9CrossRefPubMed
23.
de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–47PubMed
24.
Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407–12CrossRefPubMed
25.
Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997;350:681–6CrossRefPubMed
26.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42CrossRefPubMed
27.
Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–45CrossRefPubMed
28.
Rubio ED, Tabernero J, Cutsen EV et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. American Society of Clinical Oncology (ASCO) 2005; Abstract No: 3535
29.
Hoff PM, Eng C, Adinin RB et al. Preliminary results from a phase II study of FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC) American Society of Clinical Oncology (ASCO) 2006; Abstract No: 252
30.
Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005;16:1311–9CrossRefPubMed
31.
Bismuth H, Adam R, Levi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509–20CrossRefPubMed
32.
Zelek L, Bugat R, Cherqui D et al. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol 2003;14:1537–42CrossRefPubMed
33.
Alberts SR, Horvath WL, Sternfeld WC et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005;23:9243–9CrossRefPubMed
34.
Karoui M, Penna C, Amin-Hashem M et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006;243:1–7CrossRefPubMed
35.
Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in ninety-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:2065–72CrossRefPubMed
36.
Elias D, Cavalcanti A, de Baere T et al. [Long-term oncological results of hepatectomy performed after selective portal embolization]. Ann Chir 1999;53:559–64PubMed
37.
Pawlik TM, Izzo F, Cohen DS et al. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 2003;10:1059–69CrossRefPubMed
38.
Adam R, Laurent A, Azoulay D et al. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 2000;232:777–85CrossRefPubMed
39.
Ijichi M, Makuuchi M, Imamura H, Takayama T. Portal embolization relieves persistent jaundice after complete biliary drainage. Surgery 2001;130:116–8CrossRefPubMed
40.
Uesaka K, Nimura Y, Nagino M. Changes in hepatic lobar function after right portal vein embolization. An appraisal by biliary indocyanine green excretion. Ann Surg 1996;223:77–83CrossRefPubMed
41.
Hirai I, Kimura W, Fuse A et al. Evaluation of preoperative portal embolization for safe hepatectomy, with special reference to assessment of nonembolized lobe function with 99mTc-GSA SPECT scintigraphy. Surgery 2003;133:495–506CrossRefPubMed
42.
Vauthey JN, Chaoui A, Do KA et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 2000;127:512–9CrossRefPubMed
43.
Denys A, Madoff DC, Doenz F et al. Indications for and limitations of portal vein embolization before major hepatic resection for hepatobiliary malignancy. Surg Oncol Clin N Am 2002;11:955–68CrossRefPubMed
44.
Soyer P, Roche A, Elias D, Levesque M. Hepatic metastases from colorectal cancer: influence of hepatic volumetric analysis on surgical decision making. Radiology 1992;184:695–7PubMed
45.
Heymsfield SB, Fulenwider T, Nordlinger B et al. Accurate measurement of liver, kidney, and spleen volume and mass by computerized axial tomography. Ann Intern Med 1979;90:185–7PubMed
46.
Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br J Surg 2001;88:165–75CrossRefPubMed
47.
Vauthey JN, Abdalla EK, Doherty DA et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl 2002;8:233–40CrossRefPubMed
48.
Urata K, Kawasaki S, Matsunami H et al. Calculation of child and adult standard liver volume for liver transplantation. Hepatology 1995;21:1317–21CrossRefPubMed
49.
Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: A meta-analysis. Liver Transpl 2005;11:1481–93CrossRefPubMed
50.
Vauthey JN, Pawlik TM, Abdalla EK et al. Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg 2004;239:722–32CrossRefPubMed
51.
Abdalla EK, Barnett CC, Doherty D et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002;137:675–80CrossRefPubMed
52.
Abdalla EK, Denys A, Chevalier P et al. Total and segmental liver volume variations: implications for liver surgery. Surgery 2004;135:404–10CrossRefPubMed
53.
Kooby DA, Fong Y, Suriawinata A et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003;7:1034–44CrossRefPubMed
54.
Behrns KE, Tsiotos GG, DeSouza NF et al. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 1998;2:292–8CrossRefPubMed
55.
Azoulay D, Castaing D, Krissat J et al. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg 2000;232:665–72CrossRefPubMed
56.
Shirabe K, Shimada M, Gion T et al. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg 1999;188:304–9CrossRefPubMed
57.
Kubota K, Makuuchi M, Kusaka K et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 1997;26:1176–81PubMed
58.
Farges O, Belghiti J, Kianmanesh R et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003;237:208–17CrossRefPubMed
59.
de Baere T, Roche A, Vavasseur D et al. Portal vein embolization: utility for inducing left hepatic lobe hypertrophy before surgery. Radiology 1993;188:73–7PubMed
60.
Capussotti L, Muratore A, Ferrero A et al. Extension of Right Portal Vein Embolization to Segment IV Portal Branches. Arch Surg 2005;140:1100–3CrossRefPubMed
61.
Nagino M, Nimura Y, Kamiya J et al. Right or left trisegment portal vein embolization before hepatic trisegmentectomy for hilar bile duct carcinoma. Surgery 1995;117:677–81CrossRefPubMed
62.
Nagino M, Kamiya J, Kanai M et al. Right trisegment portal vein embolization for biliary tract carcinoma: technique and clinical utility. Surgery 2000;127:155–60CrossRefPubMed
63.
Madoff DC, Abdalla EK, Gupta S et al. Transhepatic ipsilateral right portal vein embolization extended to segment IV: improving hypertrophy and resection outcomes with spherical particles and coils. J Vasc Interv Radiol 2005;16:215–25PubMed
64.
Madoff DC, Abdalla EK, Vauthey JN. Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care. J Vasc Interv Radiol 2005;16:779–90PubMed
65.
Elias D, De Baere T, Roche A et al. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 1999;86:784–8CrossRefPubMed
66.
Kokudo N, Tada K, Seki M et al. Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology 2001;34:267–72CrossRefPubMed
67.
Abdalla EK, Smith DL, Madoff DC et al. Portal vein embolization of the entire tumor-bearing liver prior to major hepatectomy is not associated with significant tumor growth. HPB 2004;6:6 - Abstract No. 18
68.
Madoff DC, Hicks ME, Abdalla EK et al. Portal vein embolization with polyvinyl alcohol particles and coils in preparation for major liver resection for hepatobiliary malignancy: safety and effectiveness—study in 26 patients. Radiology 2003;227:251–60CrossRefPubMed
69.
Madoff DC. Portal vein embolization using polyvinyl alcohol and coils in preparation for major liver resection in patients with advanced hepatobiliary malignancy. J Vasc Interv Radiol 2001;12:S39CrossRef
70.
Shoup M, Gonen M, D’Angelica M et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 2003;7:325–30CrossRefPubMed
71.
Cady B, Jenkins RL, Steele GD, Jr. et al. Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 1998;227:566–71CrossRefPubMed
72.
Bowles BJ, Machi J, Limm WM et al. Safety and efficacy of radiofrequency thermal ablation in advanced liver tumors. Arch Surg 2001;136:864–9CrossRefPubMed
73.
Wood TF, Rose DM, Chung M et al. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000;7:593–600PubMed
74.
Bleicher RJ, Allegra DP, Nora DT et al. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann Surg Oncol 2003;10:52–8CrossRefPubMed
75.
Solbiati L, Livraghi T, Goldberg SN et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001;221:159–66CrossRefPubMed
76.
Jaeck D, Nakano H, Bachellier P et al. Significance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: a prospective study. Ann Surg Oncol 2002;9:430–8CrossRefPubMed
77.
Laurent C, Sa Cunha A, Couderc P et al. Influence of postoperative morbidity on long-term survival following liver resection for colorectal metastases. Br J Surg 2003;90:1131–6CrossRefPubMed
78.
Elias D, Ouellet JF, Bellon N et al. Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg 2003;90:567–74CrossRefPubMed
79.
Elias D, Liberale G, Vernerey D et al. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005;12:900–9CrossRefPubMed
Metadata
Title
Improving Resectability of Hepatic Colorectal Metastases: Expert Consensus Statement
Authors
Eddie K. Abdalla, MD
René Adam, MD, PhD
Anton J. Bilchik, MD, PhD
Daniel Jaeck, MD
Jean-Nicolas Vauthey, MD
David Mahvi, MD
Publication date
01-10-2006
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 10/2006
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-006-9045-5

Other articles of this Issue 10/2006

Annals of Surgical Oncology 10/2006 Go to the issue

OriginalPaper

ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes

OriginalPaper

Postresectional Adjuvant Intraportal Chemotherapy in Patients with Hepatocellular Carcinoma: A Case-Control Study

Editorial review

Selection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement by Charnsangavej et al.

OriginalPaper

AHPBA/SSO/SSAT Consensus Conference on Hepatic Colorectal Metastases: Rationale and Overview of the Conference

OriginalPaper

Selection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement

SSO Annual Meeting

Lessons Learned...